Black Diamond Therapeutics Inc (BDTX) Stock Price, Quote & News

Company Profile

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also dev...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 252 0848

Website: www.blackdiamondtherapeutics.com

Address:

245 First Street, 18th Floor, Cambridge, United States

BossTrade Sep. 1 at 3:15 AM

$BDTX Interim data is now Q4 2027 and not 1H 2028 Check out this bad boy - updated couple days ago https://clinicaltrials.gov/study/NCT07326566?intr=silevertinib&viewType=Card&rank=2

0 · Reply

BossTrade Sep. 1 at 3:02 AM

$BDTX No idea how I missed this! Time flies https://clinicaltrials.gov/study/NCT05256290?term=silevertinib&viewType=Card&rank=2 No longer recruiting. Last time I checked they still were recruiting

0 · Reply

BossTrade Sep. 1 at 2:48 AM

$BDTX Blackrock added almost +3M shares from only 917K now to 3.917M post ASCO conference may/june. Tells you all you need to know

0 · Reply

BossTrade Aug. 31 at 6:41 PM

$BDTX Typical consolidation before 50-150% move, based on chart.

0 · Reply

BossTrade Aug. 31 at 4:23 PM

$BDTX Analyst target is $8-$14 Trading at cash now. The P2 data has partnership written all over it. Very promising therapy

0 · Reply

BossTrade Aug. 31 at 3:21 PM

$BDTX FDA update for the trial and patient/trial data expected in 1-2 months. Based on data we already have seems like will be superb. Potential partnerships on the table as well As low as it gets

2 · Reply

Jackprong Aug. 27 at 4:16 PM

$BDTX Nope! Not selling!

2 · Reply

superalby Aug. 27 at 12:24 AM

$BDTX +28% last month. NSCLC best in class. Rumors about stunning preliminary data about GBM.strong cash runway. Wedbush target price $14 . TIME TO BUY OR REGRET 🚀

0 · Reply

BossTrade Aug. 21 at 9:29 PM

$BDTX Next week might be it or keeps crawling up Either way, nice move incoming

1 · Reply

BossTrade Aug. 21 at 1:48 PM

$BDTX Coming together here. A volume surge here could be $4-5 per share

0 · Reply

Raymond James keeps Outperform rating on Black Diamond Therapeutics after Q2

2026-08-06T13:18:09.000Z - 25 days ago

Black Diamond Therapeutics setup ‘attractive,’ says Jefferies

2026-08-05T20:21:24.000Z - 26 days ago

Black Diamond Therapeutics reports Q2 EPS (17c), consensus (20c)

Aug 5, 2026, 4:01 PM EDT - 26 days ago

Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Aug 5, 2026, 7:00 AM EDT - 26 days ago

Black Diamond Therapeutics Quarterly report: Q2 2026

Aug 5, 2026, 7:00 AM EDT - 26 days ago

Black Diamond Therapeutics Earnings release: Q2 2026

Jun 26, 2026, 9:00 AM EDT - 2 months ago

Black Diamond Therapeutics Transcript: AGM 2026

Jun 3, 2026, 4:55 PM EDT - 3 months ago

Black Diamond Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

May 22, 2026, 8:00 AM EDT - 3 months ago

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

May 21, 2026, 5:30 PM EDT - 3 months ago

Black Diamond Therapeutics Transcript: Study result

May 21, 2026, 5:30 PM EDT - 3 months ago

Black Diamond Therapeutics Press release: Study result

May 21, 2026, 5:13 PM EDT - 3 months ago

Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations

May 21, 2026, 7:00 AM EDT - 3 months ago

Black Diamond Therapeutics Slides: Corporate presentation

May 19, 2026, 8:00 AM EDT - 3 months ago

Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC

May 7, 2026, 7:30 AM EDT - 4 months ago

Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 7, 2026, 7:00 AM EDT - 4 months ago

Black Diamond Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 4 months ago

Black Diamond Therapeutics Earnings release: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Black Diamond Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Black Diamond Therapeutics Proxy statement: Proxy filing

2026-04-29T10:21:57.000Z - 4 months ago

Black Diamond price target raised to $11 from $10 at H.C. Wainwright

Apr 21, 2026, 10:40 AM EDT - 4 months ago

Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting

2026-03-17T11:51:25.000Z - 5 months ago

Black Diamond Therapeutics price target raised to $14 from $13 at Wedbush

2026-03-16T20:05:26.000Z - 6 months ago

Black Diamond Therapeutics reports Q4 EPS (27c), consensus (17c)

Mar 16, 2026, 4:01 PM EDT - 6 months ago

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 16, 2026, 7:00 AM EDT - 6 months ago

Black Diamond Therapeutics Earnings release: Q4 2025

Mar 16, 2026, 7:00 AM EDT - 6 months ago

Black Diamond Therapeutics Annual report: Q4 2025

Mar 4, 2026, 1:10 PM EST - 6 months ago

Black Diamond Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 4:01 PM EST - 6 months ago

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

2026-01-16T11:55:20.000Z - 8 months ago

Black Diamond Therapeutics price target lowered to $8 from $9 at Piper Sandler

Dec 4, 2025, 1:00 PM EST - 9 months ago

Black Diamond Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

2025-12-03T17:40:19.000Z - 9 months ago

Black Diamond Therapeutics downgraded to Neutral from Buy at Guggenheim

2025-12-03T17:35:12.000Z - 9 months ago

Black Diamond Therapeutics downgraded to Neutral from Buy at Guggenheim

Dec 3, 2025, 8:00 AM EST - 9 months ago

Black Diamond Therapeutics Transcript: Study Update

Dec 3, 2025, 8:00 AM EST - 9 months ago

Black Diamond Therapeutics Press release: Study Update

2025-12-03T12:11:22.000Z - 9 months ago

Black Diamond Therapeutics announces data from Phase 2 trial of silevertinib

Dec 3, 2025, 7:01 AM EST - 9 months ago

Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM

Dec 2, 2025, 4:01 PM EST - 9 months ago

Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update

2025-11-17T21:50:17.000Z - 10 months ago

Black Diamond Therapeutics assumed with an Overweight at Piper Sandler

2025-11-13T22:25:31.000Z - 10 months ago

Black Diamond Therapeutics files $500M mixed securities shelf

Nov 13, 2025, 7:00 AM EST - 10 months ago

Black Diamond Therapeutics Registration statement: Registration Filing

Nov 12, 2025, 9:00 AM EST - 10 months ago

Black Diamond Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 11, 2025, 9:20 AM EST - 10 months ago

Black Diamond Therapeutics Transcript: Stifel 2025 Healthcare Conference

2025-11-06T12:35:52.000Z - 10 months ago

Black Diamond Therapeutics reports Q3 EPS (15c), consensus (23c)

2025-11-06T12:35:40.000Z - 10 months ago

Black Diamond Therapeutics sees cash runway into 4Q27

Nov 6, 2025, 7:30 AM EST - 10 months ago

Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 6, 2025, 7:00 AM EST - 10 months ago

Black Diamond Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 10 months ago

Black Diamond Therapeutics Quarterly report: Q3 2025

Nov 5, 2025, 6:00 PM EST - 10 months ago

Black Diamond Therapeutics Slides: Corporate Presentation

2025-10-15T20:36:00.000Z - 11 months ago

Black Diamond Therapeutics resumed with a Buy at Stifel

2025-09-30T16:30:10.000Z - 11 months ago

Black Diamond Therapeutics initiated with a Buy at Freedom Capital

2025-09-04T09:25:07.000Z - 1 year ago

Black Diamond Therapeutics initiated with a Buy at Guggenheim

2025-09-03T20:15:10.000Z - 1 year ago

Black Diamond Therapeutics initiated with a Buy at Guggenheim

2025-08-11T10:21:34.000Z - 1 year ago

Black Diamond price target lowered to $10 from $12 at H.C. Wainwright

Aug 7, 2025, 7:30 AM EDT - 1 year ago

Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 7, 2025, 7:00 AM EDT - 1 year ago

Black Diamond Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 1 year ago

Black Diamond Therapeutics Quarterly report: Q2 2025

Jun 4, 2025, 4:20 PM EDT - 1 year ago

Black Diamond Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 3, 2025, 12:00 PM EDT - 1 year ago

Black Diamond Therapeutics Slides: Corporate Presentation

May 12, 2025, 4:05 PM EDT - 1 year ago

Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 12, 2025, 9:30 AM EDT - 1 year ago

Black Diamond Therapeutics Earnings release: Q1 2025

May 12, 2025, 9:30 AM EDT - 1 year ago

Black Diamond Therapeutics Quarterly report: Q1 2025

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Black Diamond Therapeutics Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Black Diamond Therapeutics Proxy statement: Proxy Filing

Apr 8, 2025, 1:00 PM EDT - 1 year ago

Black Diamond Therapeutics Transcript: Stifel 2025 Virtual Targeted Oncology Forum

Apr 7, 2025, 3:00 PM EDT - 1 year ago

Black Diamond Therapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference

Mar 19, 2025, 7:00 AM EDT - 1 year ago

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

Mar 6, 2025, 4:01 PM EST - 1 year ago

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 6, 2025, 9:30 AM EST - 1 year ago

Black Diamond Therapeutics Annual report: Q4 2024

Mar 6, 2025, 9:30 AM EST - 1 year ago

Black Diamond Therapeutics Earnings release: Q4 2024

Dec 4, 2024, 3:00 PM EST - 1 year ago

Black Diamond Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 19, 2024, 9:45 AM EST - 1 year ago

Black Diamond Therapeutics Transcript: Stifel 2024 Healthcare Conference

Nov 5, 2024, 8:00 AM EST - 1 year ago

Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 5, 2024, 7:00 AM EST - 1 year ago

Black Diamond Therapeutics Quarterly report: Q3 2024

Nov 5, 2024, 7:00 AM EST - 1 year ago

Black Diamond Therapeutics Earnings release: Q3 2024

Oct 7, 2024, 4:01 PM EDT - 2 years ago

Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway

Sep 23, 2024, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Transcript: Study Update

Sep 23, 2024, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Press release: Study Update

Sep 23, 2024, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Slides: Study Update

Sep 23, 2024, 7:00 AM EDT - 2 years ago

Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations

Sep 22, 2024, 10:00 AM EDT - 2 years ago

Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC

Sep 14, 2024, 3:30 AM EDT - 2 years ago

Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024

Aug 6, 2024, 7:30 AM EDT - 2 years ago

Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 6, 2024, 7:00 AM EDT - 2 years ago

Black Diamond Therapeutics Quarterly report: Q2 2024

Aug 6, 2024, 7:00 AM EDT - 2 years ago

Black Diamond Therapeutics Earnings release: Q2 2024

Jun 1, 2024, 10:00 AM EDT - 2 years ago

Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 1, 2024, 7:00 AM EDT - 2 years ago

Black Diamond Therapeutics Slides: Corporate Presentation

May 9, 2024, 7:30 AM EDT - 2 years ago

Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 7:00 AM EDT - 2 years ago

Black Diamond Therapeutics Quarterly report: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

Black Diamond Therapeutics Earnings release: Q1 2024

Apr 24, 2024, 4:05 PM EDT - 2 years ago

Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Proxy statement: Proxy Filing

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Proxy statement: Proxy Filing

Apr 12, 2024, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Proxy statement: Proxy Filing

Apr 11, 2024, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Announces Changes to Board of Directors

Apr 10, 2024, 12:00 PM EDT - 2 years ago

Black Diamond Therapeutics Slides: FY 2024

Apr 7, 2024, 6:00 PM EDT - 2 years ago

Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting

Apr 7, 2024, 11:00 AM EDT - 2 years ago

Black Diamond Therapeutics Slides: FY 2024

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Earnings release: Q4 2023

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Annual report: Q4 2023

Mar 5, 2024, 4:30 PM EST - 2 years ago

Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024

Feb 28, 2024, 8:00 AM EST - 2 years ago

Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Jan 4, 2024, 8:00 AM EST - 2 years ago

Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones

Dec 13, 2023, 7:00 AM EST - 2 years ago

Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM

Nov 6, 2023, 7:45 AM EST - 3 years ago

Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 6, 2023, 7:00 AM EST - 3 years ago

Black Diamond Therapeutics Quarterly report: Q3 2023

Nov 6, 2023, 7:00 AM EST - 3 years ago

Black Diamond Therapeutics Earnings release: Q3 2023

Oct 14, 2023, 12:30 PM EDT - 3 years ago

Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535

Oct 4, 2023, 12:14 PM EDT - 3 years ago

Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 18, 2023, 7:00 AM EDT - 3 years ago

Black Diamond Therapeutics Announces CEO Transition

Sep 11, 2023, 8:00 AM EDT - 3 years ago

Black Diamond Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer

Aug 11, 2023, 7:30 AM EDT - 3 years ago

Black Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 11, 2023, 7:00 AM EDT - 3 years ago

Black Diamond Therapeutics Quarterly report: Q2 2023

Aug 11, 2023, 7:00 AM EDT - 3 years ago

Black Diamond Therapeutics Earnings release: Q2 2023

Jun 29, 2023, 8:57 PM EDT - 3 years ago

Black Diamond Therapeutics Announces Pricing of Public Offering of Common Stock

Jun 28, 2023, 4:23 PM EDT - 3 years ago

Black Diamond Therapeutics Announces Proposed Public Offering of Common Stock

Jun 27, 2023, 7:00 AM EDT - 3 years ago

Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families

Jun 13, 2023, 8:00 AM EDT - 3 years ago

Black Diamond Therapeutics Announces Promotion of Melanie Morrison to Chief Development Officer

Jun 2, 2023, 8:00 AM EDT - 3 years ago

Black Diamond Therapeutics to Present at the Jefferies Healthcare Conference

May 9, 2023, 7:30 AM EDT - 3 years ago

Black Diamond Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 9, 2023, 7:00 AM EDT - 3 years ago

Black Diamond Therapeutics Quarterly report: Q1 2023

May 9, 2023, 7:00 AM EDT - 3 years ago

Black Diamond Therapeutics Earnings release: Q1 2023

Apr 18, 2023, 8:00 AM EDT - 3 years ago

Black Diamond Therapeutics to Present at the Stifel 2023 Targeted Oncology Days

Apr 17, 2023, 4:01 PM EDT - 3 years ago

Black Diamond Therapeutics Presents Trial in Progress Poster for BDTX-1535 and Preclinical Data on BDTX-1535 and BDTX-4933 at the 2023 American Association of Cancer Research Annual Meeting

Apr 4, 2023, 8:00 AM EDT - 3 years ago

Black Diamond Therapeutics Proxy statement: Proxy Filing

Apr 4, 2023, 8:00 AM EDT - 3 years ago

Black Diamond Therapeutics Proxy statement: Proxy Filing

Mar 9, 2023, 7:30 AM EST - 3 years ago

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Mar 9, 2023, 7:00 AM EST - 3 years ago

Black Diamond Therapeutics Earnings release: Q4 2022

Mar 9, 2023, 7:00 AM EST - 3 years ago

Black Diamond Therapeutics Annual report: Q4 2022

Feb 27, 2023, 8:00 AM EST - 3 years ago

Black Diamond Therapeutics to Present at the Cowen 43rd Annual Health Care Conference

Jan 5, 2023, 8:00 AM EST - 3 years ago

Black Diamond Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Dec 12, 2022, 8:00 AM EST - 4 years ago

Black Diamond Therapeutics Announces Spinout of Launchpad Therapeutics, Inc., an Antibody-Focused Precision Oncology Company

Nov 14, 2022, 7:00 AM EST - 4 years ago

Black Diamond Therapeutics Registration statement: Registration Filing

Nov 8, 2022, 8:00 AM EST - 4 years ago

Black Diamond Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

BossTrade Sep. 1 at 3:15 AM

$BDTX Interim data is now Q4 2027 and not 1H 2028 Check out this bad boy - updated couple days ago https://clinicaltrials.gov/study/NCT07326566?intr=silevertinib&viewType=Card&rank=2

0 · Reply

BossTrade Sep. 1 at 3:02 AM

$BDTX No idea how I missed this! Time flies https://clinicaltrials.gov/study/NCT05256290?term=silevertinib&viewType=Card&rank=2 No longer recruiting. Last time I checked they still were recruiting

0 · Reply

BossTrade Sep. 1 at 2:48 AM

$BDTX Blackrock added almost +3M shares from only 917K now to 3.917M post ASCO conference may/june. Tells you all you need to know

0 · Reply

BossTrade Aug. 31 at 6:41 PM

$BDTX Typical consolidation before 50-150% move, based on chart.

0 · Reply

BossTrade Aug. 31 at 4:23 PM

$BDTX Analyst target is $8-$14 Trading at cash now. The P2 data has partnership written all over it. Very promising therapy

0 · Reply

BossTrade Aug. 31 at 3:21 PM

$BDTX FDA update for the trial and patient/trial data expected in 1-2 months. Based on data we already have seems like will be superb. Potential partnerships on the table as well As low as it gets

2 · Reply

Jackprong Aug. 27 at 4:16 PM

$BDTX Nope! Not selling!

2 · Reply

superalby Aug. 27 at 12:24 AM

$BDTX +28% last month. NSCLC best in class. Rumors about stunning preliminary data about GBM.strong cash runway. Wedbush target price $14 . TIME TO BUY OR REGRET 🚀

0 · Reply

BossTrade Aug. 21 at 9:29 PM

$BDTX Next week might be it or keeps crawling up Either way, nice move incoming

1 · Reply

BossTrade Aug. 21 at 1:48 PM

$BDTX Coming together here. A volume surge here could be $4-5 per share

0 · Reply

investfreakycat Aug. 21 at 4:21 AM

$BDTX very interesting setup🤫time for the breakout

0 · Reply

superalby Aug. 20 at 11:07 AM

$BDTX

0 · Reply

superalby Aug. 19 at 8:09 PM

$BDTX someone loading the boat...

0 · Reply

BossTrade Aug. 19 at 1:48 PM

$BDTX 2.17 and volume hasn’t even come in! Love it

1 · Reply

superalby Aug. 19 at 7:09 AM

$BDTX lets break 2.20 and fly 🚀

0 · Reply

BossTrade Aug. 17 at 2:38 PM

$BDTX Couldn’t resist to add. Very strongly positioned for 2-3x

0 · Reply

Marklacey123 Aug. 12 at 10:48 AM

$BDTX Good News Black Diamond Therapeutics Inc. settled HMI Medical Innovations LLC’s lawsuit alleging its development of cancer therapies using lab-based systems to find and refine drug candidates infringes six patents. The companies notified the US District Court for the District of Delaware on Tuesday that they reached a confidential settlement and license agreement, and asked the court to dismiss the suit with prejudice. Judge Jennifer L. Hall approved the dismissal the same day. HMI alleged the infringement was tied to Black Diamond therapies including silevertinib, a fourth-generation drug that blocks a cancer-driving protein called EGFR and targets lung cancer and glioblastoma

0 · Reply

superalby Aug. 12 at 10:30 AM

$BDTX blackrock is buying... i shouldnt have post here. Now they follow my lead 😜

0 · Reply

superalby Aug. 11 at 11:12 PM

$BDTX end of october after fda pivotal ,big pharma is stepping in. No doubt. $ 8 is the minimum for this kind of asset ( unmet need, break resistance , brain penetrant, zero de novo methastasis). Who is smart is jumping in now... the others will regret.

0 · Reply

Acho5280 Aug. 11 at 11:09 PM

$BDTX Might show up on the momentum traders' list if we get news.

1 · Reply

BossTrade Aug. 11 at 7:11 PM

$BDTX Upper tier upward consolidation Let’s test that $4.80 and blast into DD

0 · Reply

BossTrade Aug. 11 at 3:44 PM

$BDTX You’re way ahead of yourself here. If we were at that stage now, this would be at least $50 a share now

1 · Reply

Market Cap	128.12M
Revenue (ttm)	70.00M
Net Income (ttm)	22.37M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	31.96%
Debt to Equity Ratio	0.00

Volume	509,200
Avg Vol	1,126,788
Day's Range	N/A - N/A
Shares Out	57.45M
Stochastic %K	8%
Beta	3.28
Analysts	Strong Sell
Price Target	$9.06